FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:	APPLICATION NO.:
OC01626K	**10/666,424**
APPLICANT: **Kamil Paruch *et al.***	
FILING DATE: **9/19/2003**	GROUP:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
✓	AL	EP 0 778 277	06/11/1997	EPO				
✓	AM	WO 02/06286	01/24/2002	PCT				
✓	AN	WO 88/04298	06/16/1988	PCT				
	AO							
	AP							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

✓	AQ	Vesely *et al.*, "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", *Eur. J. Biochem* (1994), **224**: 771-785.
✓	AR	Senderowicz *et al.*, "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", *Journal of Clinical Oncology* (September 1998), **16**(9): 2986-2999.
✓	AS	Meijer *et al.*, "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", *Eur. J. Biochem.* (1997), **243**: 527-536.
✓	AT	Bible *et al.*, "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", *Cancer Research* (August 15, 1997), **57**: 3375-3380.
✓	AU	Shiota *et al.*, "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", *Chem. Pharm. Bull.* (1999), **47**(7): 928-938.
✓	AV	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.", *Chem. Pharm. Bull.* (1962), **10**: 620-626.

EXAMINER	DATE CONSIDERED
	6/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:	APPLICATION NO.:
OC01626K	**10/666,424**
APPLICANT: **Kamil Paruch *et al.***	
FILING DATE: **09/19/2003**	GROUP:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
✓	AL	**WO 2002 060492 A**	**08/08/2002**	**WIPO**				
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AQ	
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER [signature] DATE CONSIDERED 6/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01626K	APPLICATION NO.: 10/666,424
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Kamil Paruch *et al.*	
(Use several sheets if necessary)		FILING DATE: 09/19/2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AW						
	AX						
	AY						
	AZ						
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
✓	BH	**WO 02/10162**	**02/07/2002**	**WIPO**				
	BI							
	BJ							
	BK							
	BL							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

✓	BM	A. Sanderowicz *et al.*, "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", *J. Clin. Oncology*, **16**: 2986-2999 (1998).
✓	BN	J. Vesely *et al.*, "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", *Eur. J. Biochem.*, **224**: 771-786 (1994).
✓	BO	I. Meijer *et al.*, "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", *Eur. J. Biochem.*, **243**: 527-536 (1997).
✓	BP	K. S. Kim *et al.*, "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", *J. Medicinal Chemistry*, **45**: 3905-3927 (2002)
	BQ	
	BR	

EXAMINER	DATE CONSIDERED
[signature]	6/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:	APPLICATION NO.:
OC01626K	**10/666,424**
APPLICANT: **Kamil Paruch *et al.***	
FILING DATE: **09/19/2004**	GROUP:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
✓	AL	**WO 03/089434**	**10/30/2003**	**WIPO**				
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AQ	
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER [signature] DATE CONSIDERED 6/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.